Israel Englander’s Exagen XGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-56,069
Closed -$168K 6471
2026
Q1
$168K Sell
56,069
-168,540
-75% -$652K ﹤0.01% 5229
2025
Q4
$1.37M Sell
224,609
-22,564
-9% -$205K ﹤0.01% 4251
2025
Q3
$2.72M Buy
+247,173
New +$2.19M ﹤0.01% 3759
2025
Q1
Sell
-15,862
Closed -$65K 6473
2024
Q4
$65K Sell
15,862
-6,649
-30% -$24K ﹤0.01% 5550
2024
Q3
$69.6K Buy
22,511
+8,108
+56% +$21K ﹤0.01% 5650
2024
Q2
$26.2K Sell
14,403
-9,457
-40% -$16K ﹤0.01% 5500
2024
Q1
$37.9K Buy
23,860
+245
+1% +$476 ﹤0.01% 5728
2023
Q4
$47K Sell
23,615
-7,606
-24% -$13.2K ﹤0.01% 5487
2023
Q3
$76.5K Buy
31,221
+1,216
+4% +$3.08K ﹤0.01% 5398
2023
Q2
$87K Sell
30,005
-3,150
-10% -$8.96K ﹤0.01% 5358
2023
Q1
$81K Sell
33,155
-3,432
-9% -$8.87K ﹤0.01% 5490
2022
Q4
$88K Sell
36,587
-12,921
-26% -$33.1K ﹤0.01% 5624
2022
Q3
$134K Sell
49,508
-30,121
-38% -$168K ﹤0.01% 5857
2022
Q2
$457K Buy
+79,629
New +$464K ﹤0.01% 5032
2022
Q1
Sell
-29,294
Closed -$341K 7566
2021
Q4
$341K Sell
29,294
-5,657
-16% -$66.3K ﹤0.01% 5414
2021
Q3
$475K Sell
34,951
-41,107
-54% -$546K ﹤0.01% 5403
2021
Q2
$1.14M Buy
+76,058
New +$1.17M ﹤0.01% 4541
2019
Q4
Sell
-37,964
Closed -$588K 4690
2019
Q3
$588K Buy
+37,964
New +$613K ﹤0.01% 3153

Other funds holding XGN

Israel Englander's XGN Position: Q2 2026 in Review

Israel Englander sold out of Exagen (XGN) in Q2 2026, closing a stake of 56,069 shares — an estimated $168K sold.

Israel Englander first reported a position in XGN in Q3 2019 and held it in 18 quarters. The position peaked at $2.72M in Q3 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • Israel Englander reported no remaining Exagen position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 56,069 Exagen shares in Q2 2026, an estimated $168K.
  • Israel Englander first reported a position in Exagen in Q3 2019 and held it in 18 quarters.
  • Israel Englander's Exagen position peaked at $2.72M in Q3 2025.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.